Advanced

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer

Robinson, David; Sandblom, Gabriel LU ; Johansson, Robert; Garmo, Hans; Aus, Gunnar; Hedlund, Per Olov and Varenhorst, Eberhard (2008) In Urology 72(4). p.903-907
Abstract
OBJECTIVES To assess the value of prostate-specific antigen (PSA) kinetics in predicting survival and relate this to the baseline variables in men with metastatic hormone-refractory prostate cancer (HRPC). METHODS The data from 417 men with HRPC were included in a. logistic regression model that included hemoglobin, PSA, alkaline phosphatase, Soloway score, and performance status pain analgesic score at baseline. The posttreatment variables included the PSA level halving time after the start of treatment, PSA level at nadir, interval to nadir, PSA velocity (PSAV), PSA doubling time after reaching a nadir, patient age, and treatment. These variables were added to the baseline model, forming. new logistic regression models that were tested... (More)
OBJECTIVES To assess the value of prostate-specific antigen (PSA) kinetics in predicting survival and relate this to the baseline variables in men with metastatic hormone-refractory prostate cancer (HRPC). METHODS The data from 417 men with HRPC were included in a. logistic regression model that included hemoglobin, PSA, alkaline phosphatase, Soloway score, and performance status pain analgesic score at baseline. The posttreatment variables included the PSA level halving time after the start of treatment, PSA level at nadir, interval to nadir, PSA velocity (PSAV), PSA doubling time after reaching a nadir, patient age, and treatment. These variables were added to the baseline model, forming. new logistic regression models that were tested for net reclassification improvement. RESULTS The area under the receiver operating characteristics curve for the baseline model was 0.67. Of all variables related to PSA kinetics, the PSAV was the best predictor. The addition of PSAV to the baseline model increased the area under the receiver operating characteristics curve to 0.81. Only a moderate increase in the area under the receiver operating characteristics curve (0.83) was achieved by combining the baseline model in a multivariate model with PSAV, PSA doubting time, interval to nadir, and patient age at diagnosis of HRPC. CONCLUSIONS The PSAV alone gave a better prediction of survival value than all other PSA kinetics variables. By combining PSAV with the variables available at baseline, a better ground for treatment decision-making in men with HRPC can be achieved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Urology
volume
72
issue
4
pages
903 - 907
publisher
Elsevier
external identifiers
  • wos:000259845600045
  • scopus:52949136987
ISSN
1527-9995
DOI
10.1016/j.urology.2008.05.026
language
English
LU publication?
yes
id
c4681036-5c05-471c-9785-dddf5bdb5458 (old id 1286165)
date added to LUP
2009-02-04 09:13:30
date last changed
2017-01-01 05:14:35
@article{c4681036-5c05-471c-9785-dddf5bdb5458,
  abstract     = {OBJECTIVES To assess the value of prostate-specific antigen (PSA) kinetics in predicting survival and relate this to the baseline variables in men with metastatic hormone-refractory prostate cancer (HRPC). METHODS The data from 417 men with HRPC were included in a. logistic regression model that included hemoglobin, PSA, alkaline phosphatase, Soloway score, and performance status pain analgesic score at baseline. The posttreatment variables included the PSA level halving time after the start of treatment, PSA level at nadir, interval to nadir, PSA velocity (PSAV), PSA doubling time after reaching a nadir, patient age, and treatment. These variables were added to the baseline model, forming. new logistic regression models that were tested for net reclassification improvement. RESULTS The area under the receiver operating characteristics curve for the baseline model was 0.67. Of all variables related to PSA kinetics, the PSAV was the best predictor. The addition of PSAV to the baseline model increased the area under the receiver operating characteristics curve to 0.81. Only a moderate increase in the area under the receiver operating characteristics curve (0.83) was achieved by combining the baseline model in a multivariate model with PSAV, PSA doubting time, interval to nadir, and patient age at diagnosis of HRPC. CONCLUSIONS The PSAV alone gave a better prediction of survival value than all other PSA kinetics variables. By combining PSAV with the variables available at baseline, a better ground for treatment decision-making in men with HRPC can be achieved.},
  author       = {Robinson, David and Sandblom, Gabriel and Johansson, Robert and Garmo, Hans and Aus, Gunnar and Hedlund, Per Olov and Varenhorst, Eberhard},
  issn         = {1527-9995},
  language     = {eng},
  number       = {4},
  pages        = {903--907},
  publisher    = {Elsevier},
  series       = {Urology},
  title        = {PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer},
  url          = {http://dx.doi.org/10.1016/j.urology.2008.05.026},
  volume       = {72},
  year         = {2008},
}